

---

## **Dermavant is committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.**

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

---

## **Dermavant at-a-glance**

- Clinical-stage biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, California and Raleigh-Durham, North Carolina

---

## **About Dermavant**

### **A Passion for Science and a Commitment to Dermatology**

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage bio-pharmaceutical company focused on developing products that represent new treatment categories and address some of the greatest challenges providers and patients encounter.

The company's robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immune-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.

Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 28 million people in the United States, respectively.

---

## **Management team**

### **Todd Zavodnick**

Chief Executive Officer

---

### **Cyril Allouche**

Chief Financial Officer

---

### **Philip M. Brown, MD, JD**

Chief Medical Officer

---

### **Chris Chapman**

Chief Commercial Officer

---

### **David Rubenstein, MD, PhD**

Chief Scientific Officer

---

### **Christopher Van Tuyl, JD**

General Counsel

---

# Dermavant has five product candidates addressing:

Psoriasis · Atopic Dermatitis · Vitiligo · Hyperhidrosis · Acne

PRODUCT CANDIDATE	INDICATION	STAGE OF DEVELOPMENT			
		Preclinical	Phase 1	Phase 2	Phase 3
<b>Tapinarof (DMVT-505)</b> A topical, therapeutic AhR modulating agent (TAMA), inhibiting several proinflammatory factors	Psoriasis	[Progress bar: Preclinical to Phase 3]			
	Atopic Dermatitis	[Progress bar: Preclinical to Phase 3]			
<b>Cerdulatinib (DMVT-502)</b> A topical dual JAK/Syk inhibitor	Vitiligo	[Progress bar: Preclinical to Phase 2]			
	Atopic Dermatitis	[Progress bar: Preclinical to Phase 2]			
<b>Oxybutynin/Pilocarpine (DMVT-504)</b> An oral combination of an immediate-release muscarinic antagonist with a delayed-release muscarinic agonist	Primary Focal Hyperhidrosis	[Progress bar: Preclinical to Phase 2]			
<b>DMVT-503</b> A novel mechanism of action for the topical treatment of acne vulgaris	Acne Vulgaris	[Progress bar: Preclinical to Phase 1]			
<b>Lotamilast (DMVT-501)</b> A highly selective topical PDE4 inhibitor	Atopic Dermatitis	[Progress bar: Preclinical to Phase 1]			

Excludes certain Asian territories

## Key U.S. market data as of 2019

### Psoriasis: 8M patients<sup>1</sup>

- \$12.0B sales<sup>2</sup>
- \$19.3B by 2026<sup>2</sup>
- Topical treatments are ~80% of U.S. RxS<sup>3,4</sup>

### Atopic dermatitis: 28M patients<sup>5</sup>

- \$1.8B sales<sup>2</sup>
- \$5.7B by 2026<sup>2</sup>
- Topical treatments are ~97% of U.S. RxS<sup>3,4</sup>

### Vitiligo: 2.4M patients<sup>6</sup>

- No FDA-approved therapies

### Hyperhidrosis: 15.3M patients<sup>7</sup>

- No FDA-approved systemic treatments

**References:** 1. National Psoriasis Foundation. 2. Evaluate Pharma. 3. IQVIA NDTI 2020. 4. Symphony Prescriber Source 2020. 5. National Eczema Association. 6. Rose & Mackay, US Census. 7. Doolittle, J. et al. Arch Dermatol Res, 2016, 308:743-749; US Census.

**Main Phone Number:** 919-767-3277

#### Company locations:

**Long Beach, California Office**  
 Dermavant Sciences, Inc.  
 3780 Kilroy Airport Way, Suite 250  
 Long Beach, CA 90806

**Raleigh-Durham, North Carolina Office**  
 Dermavant Sciences, Inc.  
 3300 Paramount Parkway, Suite 150  
 Morrisville, NC 27560

**Basel, Switzerland Office**  
 Dermavant Sciences GmbH  
 Viaduktstrasse 8  
 4051 Basel